Explore diffuse large B-cell lymphoma — symptoms, causes, diagnosis, treatment options, and prevention. Learn about its types ...

Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen ...

FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...

Combination Targeted Treatment Produces Lasting Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19, 2024 — Researchers have developed a non-chemotherapy treatment regimen ...

Lyell Immunopharma’s ($LYEL) jumped over 8% on Friday as investors’ interest surged. Despite posting unimpressive Q4 results ...

Wojciech Jurczak, MD, PhD, discusses advancements in B-cell lymphoma therapy, focusing on immunotherapy, molecular-targeted agents, and more.

The following is a summary of “Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With ...

AstraZeneca has recently been investing heavily in the cell therapy space, including two acquisitions for TeneoTwo and ...

Enhanced assay granted approval by New York State’s Clinical Lab Evaluation Program (CLEP) for patients with DLBCL clonoSEQ is the only DLBCL MRD ...

CEO Gina Chapman is also departing the company, which plans to review options for pursuing a reverse merger or other business ...

Matthew Matasar, MD, discussed what the findings from the ELM-1 trial of odronextamab in diffuse large B-cell lymphoma mean ...